List of Excipients in Branded Drug PLIAGLIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Taro Pharmaceuticals USA Inc	PLIAGLIS	lidocaine and tetracaine	51672-5305	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	2031-01-14
Taro Pharmaceuticals USA Inc	PLIAGLIS	lidocaine and tetracaine	51672-5305	METHYLPARABEN	2031-01-14
Taro Pharmaceuticals USA Inc	PLIAGLIS	lidocaine and tetracaine	51672-5305	PETROLATUM	2031-01-14

Pliaglis Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Manufacturing Analysis

Last updated: August 24, 2026

Pliaglis is a prescription topical anesthetic cream containing lidocaine 7% and tetracaine 7%. Its commercial differentiation comes from a film-forming cream that dries on the skin and permits removal before a dermatologic or cosmetic procedure. The principal excipient opportunity is not a simple substitution program. It is the development of a cream that matches Pliaglis’ anesthetic delivery, drying behavior, peelability, skin feel, stability, preservative performance, and manufacturing economics.

The strongest commercial opportunities are generic or authorized-generic entry, contract development of equivalent topical anesthetic products, improved film-forming systems, preservative and packaging optimization, and geographic expansion outside the United States. The main technical barrier is reproducing the product’s drug release and dry-film performance while maintaining regulatory comparability.

What is Pliaglis and how does its formulation work?

Pliaglis contains 7% lidocaine and 7% tetracaine in a topical cream. It is applied to intact skin before procedures such as laser treatment, injectable procedures, and other dermatologic interventions. The cream dries to form a pliable membrane that can be removed before the procedure. The drying step is central to product performance because it affects drug residence time, handling, removal, and patient acceptance.

What are the labeled Pliaglis excipients?

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation role
Purified water	Continuous aqueous phase and processing medium
Calcium phosphate	Mineral structurant, opacity and rheology modifier
Polyvinyl alcohol	Film-forming polymer
Liquid paraffin	Emollient and oil-phase component
Sorbitan monopalmitate	Nonionic emulsifier
Methylparaben	Preservative
Propylparaben	Preservative

The listed excipients create a water-in-oil or complex emulsion system with a film-forming polymer. Polyvinyl alcohol is the key excipient from a product-performance perspective. Calcium phosphate and the oil phase influence viscosity, opacity, drying, and the mechanical properties of the removable film. Methylparaben and propylparaben provide a conventional preservative system for a multidose topical product. [1]

The public label does not disclose quantitative excipient concentrations. That limits direct reverse engineering from the label alone. Competitors must rely on formulation development, analytical characterization, patent review, and comparative performance testing.

What excipient functions must a Pliaglis competitor reproduce?

A commercially viable equivalent must reproduce multiple attributes simultaneously:

1. Uniform delivery of lidocaine and tetracaine across the applied skin area.
2. Adequate viscosity for controlled application without excessive spreading.
3. Drying within a clinically acceptable period.
4. Formation of a continuous, flexible, removable film.
5. Stable drug content and preservative performance during shelf life.
6. Acceptable odor, appearance, residue, and skin feel.
7. Compatibility with the commercial container and closure.
8. Consistent removal without excessive rubbing or tearing.

A formulation that matches drug strength but produces a brittle, tacky, slow-drying, or difficult-to-remove film is unlikely to achieve commercial parity.

Which excipients are most important to formulation performance?

Polyvinyl alcohol is the most strategically important listed excipient because it controls film formation. Its molecular weight, degree of hydrolysis, solution viscosity, concentration, and interaction with the emulsion phase can alter drying time and film strength.

Calcium phosphate can affect opacity, density, viscosity, and suspension behavior. Particle size and surface characteristics may influence both application feel and batch-to-batch uniformity.

Liquid paraffin contributes to emolliency and can reduce the dry, tight sensation associated with aqueous polymer films. Its concentration also affects evaporation, film flexibility, and the ability to remove the dried layer.

Sorbitan monopalmitate supports emulsion structure. Changes in emulsifier type or level can alter droplet size, phase separation, drug distribution, and long-term stability.

The preservative pair is commercially relevant because parabens may create consumer-preference, regional-market, or retailer-positioning issues. A paraben-free alternative would require evidence that antimicrobial protection, skin tolerability, chemical stability, and product preservation remain adequate.

What formulation strategies can improve Pliaglis or create a competing product?

The most attractive strategy is a controlled reformulation that preserves the film-forming mechanism while improving one or more commercial attributes.

Faster-drying film systems

A faster-drying product could reduce waiting time before a procedure. Candidate approaches include:

• Adjusting the water-to-oil ratio.
• Using volatile co-solvents, subject to skin-safety and labeling constraints.
• Modifying polyvinyl alcohol grade or concentration.
• Introducing a secondary film-forming polymer.
• Reducing the wet-film thickness required for effective coverage.
• Optimizing packaging and applicator geometry to produce a uniform layer.

The primary development risk is that faster evaporation can produce a brittle film, uneven drug distribution, increased skin tightness, or reduced removal performance.

Improved peelability and skin feel

A softer, more flexible dry film could improve patient and clinician acceptance. Potential approaches include changing the ratio of polymer to emollient, adding a compatible plasticizer, or using a polymer blend. Candidate materials must be evaluated for:

• Drug diffusion.
• Film tensile strength.
• Residual tack.
• Removal force.
• Skin irritation.
• Interaction with the preservative system.

A plasticizer that improves flexibility may slow drying or increase residue. The optimal product will balance these effects rather than maximize a single film attribute.

Preservative-system alternatives

A paraben-free product could support differentiated positioning in selected markets. Possible systems include phenoxyethanol-based, organic-acid-based, or multifunctional preservative approaches. The choice depends on formulation pH, water activity, emulsion structure, packaging, and regional regulatory acceptance.

Preservative replacement is not a low-risk substitution. It can change emulsion stability, odor, skin tolerability, and microbial challenge-test performance. The most practical route may be a package-preservative strategy using a low-permeability tube or airless container to reduce contamination during use.

Packaging and delivery-system improvements

Pliaglis is a semisolid topical product, so the container is part of the commercial proposition. Opportunities include:

• Unit-dose sachets for procedure clinics.
• Metered-dose dispensers for reproducible coverage.
• Airless pumps to reduce contamination and oxidation.
• Narrow-orifice tubes that improve dose control.
• Packaging designed for clinic workflow and rapid application.
• Tamper-evident, single-patient packaging for aesthetic practices.

Unit-dose packaging may increase cost per gram but reduce waste and improve dose consistency. It may also support institutional purchasing and procedure kits.

What FDA regulatory pathway applies to a competing Pliaglis product?

Pliaglis is regulated as a prescription drug under an approved new drug application. The reference product is associated with NDA 021659. A generic competitor would ordinarily pursue an abbreviated new drug application if it can satisfy the applicable sameness and bioequivalence requirements. [1][2]

For a topical cream containing two active ingredients, the development program may require more than conventional plasma pharmacokinetic testing. Relevant evidence can include:

• Pharmaceutical equivalence.
• Qualitative and quantitative sameness or permitted inactive-ingredient differences.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing.
• Comparative product performance.
• Microbiological quality and preservative effectiveness.
• Container-closure compatibility.
• Stability data.

FDA’s topical-product guidance places significant emphasis on product quality, sameness, and performance testing. A materially different excipient system may increase regulatory complexity and could push a sponsor toward a 505(b)(2) strategy rather than a conventional ANDA, depending on the proposed differences and FDA’s requirements. [3]

Are excipient changes allowed in an ANDA?

Yes, but the scope is constrained. FDA may permit differences in inactive ingredients when the proposed formulation remains pharmaceutically equivalent and the excipients do not affect safety, performance, or bioequivalence. For a film-forming topical cream, differences in polymer, emulsifier, preservative, or oil phase can have a direct effect on drug release and skin delivery.

The commercial decision is therefore a tradeoff:

Strategy	Regulatory advantage	Commercial limitation
Close Q1/Q2 formulation	Lower comparability risk	Limited product differentiation
Modified excipient system	Potentially better performance	Greater bioequivalence and CMC burden
New delivery system	Strong differentiation	Higher development and regulatory cost
Authorized generic	Faster market access if available	Depends on brand-owner arrangement

What patents protect Pliaglis and when does exclusivity expire?

Pliaglis’ current market protection must be assessed through the FDA Orange Book, issued patents, terminal disclaimers, patent-term adjustments, pediatric extensions, and any litigation or settlement records. The Orange Book identifies patents and exclusivity associated with approved drug products, but an Orange Book listing does not establish that every listed patent will withstand challenge. [2]

The commercial relevance of Pliaglis patent protection is likely concentrated in claims directed to:

• Topical compositions containing lidocaine and tetracaine.
• Film-forming topical anesthetic systems.
• Specific excipient combinations.
• Drying and removal characteristics.
• Methods of anesthetizing skin before procedures.
• Packaging or application methods.

A competitor should separate three categories of protection:

1. Core composition claims.
2. Formulation and delivery claims.
3. Method-of-use claims.

A narrow excipient claim may be avoided through a different polymer, emulsifier, preservative, or oil-phase composition. A broad claim covering a film-forming anesthetic composition could present a larger barrier. Method-of-use claims may remain relevant even after core composition claims expire if the labeled indication and use instructions overlap.

How strong is the Pliaglis patent estate?

The estate is strongest where patent claims are tied to measurable product attributes that are difficult to design around, such as a defined film-forming system, specific drug ratios, drying behavior, or removal properties. It is weaker where claims depend on broad excipient categories that can be replaced without changing the clinical function of the product.

Patent strength should be evaluated claim by claim against the proposed formulation. A generic formulation that uses a different polymer family and avoids claimed concentration ranges may reduce infringement risk, but it still must meet FDA performance requirements.

When does Pliaglis lose exclusivity and what are the generic launch scenarios?

Pliaglis has been marketed for many years, so the principal commercial question is no longer basic regulatory exclusivity. It is the remaining enforceable patent and litigation position, together with the economics of developing a dual-active topical product.

Potential launch scenarios include:

Scenario	Market effect
No viable Paragraph IV challenge	Continued brand-led market with limited direct generic pressure
Paragraph IV certification without settlement	Litigation may delay launch under the Hatch-Waxman framework
Settlement with an agreed entry date	Predictable generic entry but potentially limited early competition
Successful patent invalidity or non-infringement case	Earlier market opening
Authorized generic launch	Immediate price pressure without an independent ANDA competitor
505(b)(2) differentiated product	Potentially later entry with stronger product positioning

A Paragraph IV challenger must address listed patents and provide the required certification to the NDA holder and patent owner. The patent holder may file suit within the statutory period, creating a potential 30-month stay of approval under applicable Hatch-Waxman rules. [4]

The absence of a public litigation discussion in commercial materials should not be treated as evidence that no challenge exists. Generic filings, patent certifications, settlements, and litigation events must be assessed through FDA, court, and company disclosures.

What generic entry risks exist for Pliaglis?

The principal risks are technical rather than active-ingredient risk. Lidocaine and tetracaine are established local anesthetics, but the combination’s topical performance depends on the formulation.

Key generic-entry risks include:

• Failure to match in vitro release.
• Inconsistent film formation across batches.
• Uneven drug distribution during application.
• Preservative failure after repeated opening.
• Phase separation during accelerated stability testing.
• Container adsorption or drug loss.
• Skin irritation from a substitute preservative or solvent.
• Difficulty demonstrating equivalence for a complex topical product.
• Patent claims covering the film-forming system rather than only the active ingredients.

A close formulation may minimize regulatory risk but increase exposure to composition patents. A redesigned formulation may reduce patent overlap but increase development cost and FDA comparability risk.

Which commercial opportunities exist for Pliaglis excipients?

Generic and authorized-generic development

The highest-value opportunity is a formulation that delivers equivalent anesthetic performance at lower manufacturing cost. Cost reductions may come from:

• Improved mixing and heating cycles.
• Lower-cost qualified sources of polyvinyl alcohol.
• Simplified preservative handling.
• Reduced batch rejects caused by viscosity variation.
• More efficient filling and packaging.
• Unit-dose formats for high-volume procedural practices.

A generic cream must compete on more than acquisition price. Dermatology and aesthetic clinics value predictable drying time, clean removal, consistent coverage, and reliable supply.

Contract manufacturing and formulation licensing

Companies with expertise in topical emulsions can license:

• A non-infringing film-forming platform.
• A paraben-free Pliaglis-like formulation.
• A faster-drying cream.
• A unit-dose or metered-dose presentation.
• Regional rights for markets where the U.S. product is not marketed.

The most licensable asset is likely a validated formulation platform with comparative release, stability, and skin-performance data rather than an untested excipient concept.

Geographic expansion

Pliaglis’ commercial potential varies by jurisdiction. The product may require separate approvals, local trademarks, pricing strategies, and patent analysis in Europe, Canada, Latin America, Asia-Pacific, and the Middle East. A sponsor could pursue regional products using the same active ingredients but adapt preservatives, packaging, or excipients to local requirements.

Geographic expansion is more attractive where dermatology, aesthetic medicine, laser procedures, and injectable treatments have established private-pay demand. Commercial success depends on reimbursement, physician preference, local anesthetic competition, and regulatory classification.

Adjacent product categories

A Pliaglis-derived platform could support:

• Pre-injection anesthetic products.
• Laser and light-based procedure products.
• Microneedling and superficial dermatology products.
• Clinic procedure kits.
• Pediatric or needle-phobia applications where permitted by labeling.
• Products with shorter application times.
• Products with lower residue and easier cleanup.

Any new indication or patient population could create method-of-use patent opportunities, but clinical and regulatory evidence would be required.

How does Pliaglis compare with conventional lidocaine-prilocaine creams?

Pliaglis differs from conventional lidocaine-prilocaine cream products in active ingredients, concentration, and delivery behavior. Lidocaine-prilocaine creams typically rely on an occlusive application period and do not use the same removable dry-film concept. Pliaglis therefore competes on workflow and procedural convenience as well as anesthetic effect.

Attribute	Pliaglis	Conventional lidocaine-prilocaine cream
Active ingredients	Lidocaine 7% and tetracaine 7%	Usually lidocaine and prilocaine
Delivery format	Film-forming topical cream	Conventional cream
Removal	Dried membrane can be removed	Often wiped or washed off
Differentiation	Drying, peelability, clinic workflow	Familiarity and broad availability
Excipient opportunity	Film polymer and emulsion design	Occlusion, cream texture, penetration
Generic risk	Complex topical comparability	More established generic pathways in some markets

Pliaglis can command a premium if it reduces preparation time or improves procedure-room handling. A lower-cost generic could erode that premium quickly if it matches drying and removal performance.

What FDA regulatory and Orange Book status matters commercially?

The reference product’s NDA, labeling, approved strength, dosage form, and listed patents determine the baseline for generic strategy. FDA’s Orange Book should be used to identify:

• NDA 021659.
• Current patent listings.
• Pediatric exclusivity, if applicable.
• Regulatory exclusivity codes.
• Approved dosage form and strength.
• Reference-product designation relevant to an ANDA.

FDA’s Inactive Ingredient Database can support excipient selection by showing prior use of ingredients in approved products. It does not, by itself, establish acceptability for the proposed concentration, route, dosage form, or patient population. [5]

What is the revenue exposure and competitive landscape?

Standalone Pliaglis revenue is not generally disclosed as a separate public reporting line. Taro Pharmaceuticals reports broader business performance rather than detailed product-level revenue for Pliaglis. [6] This limits precise valuation of brand erosion or generic-entry exposure.

The competitive set includes:

• Generic or branded lidocaine-prilocaine creams.
• Tetracaine-containing topical products.
• Lidocaine patches and gels.
• Injectable local anesthetics used by clinicians.
• Compounded topical anesthetics.
• New topical anesthetic delivery systems.

Pliaglis has a narrower but potentially higher-value niche than standard topical anesthetics. Its commercial defense depends on physician familiarity, procedure-clinic workflow, supply reliability, and the difficulty of matching its film-forming performance.

Key Takeaways

• Pliaglis contains lidocaine 7% and tetracaine 7% in a film-forming topical cream.
• The labeled excipients are purified water, calcium phosphate, polyvinyl alcohol, liquid paraffin, sorbitan monopalmitate, methylparaben, and propylparaben.
• Polyvinyl alcohol is the central excipient for drying and removable-film performance.
• The strongest generic opportunity is a close equivalent with lower manufacturing cost and validated in vitro performance.
• The strongest differentiated opportunity is a faster-drying, softer, cleaner-removing, or preservative-optimized product.
• Excipient substitution can create both patent-design-around value and FDA comparability risk.
• Patent analysis must cover composition, formulation, method-of-use, packaging, Orange Book listings, and litigation or settlement records.
• Standalone Pliaglis revenue is not separately disclosed, so market sizing should use procedure volume, clinic purchasing, pricing, and competitor share rather than reported product revenue.
• Unit-dose packaging and clinic-oriented delivery systems are commercially credible extensions.
• The primary barrier is reproducing the complete product profile, not sourcing the active ingredients.

FAQs

Can polyvinyl alcohol be replaced in a Pliaglis generic?

Yes, but replacement can materially change drying time, film strength, removal force, drug release, and skin feel. The substitute polymer would require comparative performance and regulatory support.

Is a paraben-free Pliaglis formulation commercially attractive?

It can be attractive for selected markets and clinic customers, particularly where preservative preferences affect purchasing. The formulation must still pass preservative effectiveness, stability, skin-tolerability, and product-performance testing.

Could Pliaglis be sold as an over-the-counter product?

The marketed product is prescription-only in the United States. An OTC pathway would require an applicable monograph or an FDA-approved switch supported by regulatory and clinical evidence.

Is Pliaglis suitable for an authorized-generic strategy?

Yes. An authorized generic could use the approved or substantially equivalent formulation and compete through lower price, clinic supply contracts, and alternate packaging. Commercial feasibility depends on the brand owner’s licensing posture and manufacturing economics.

What is the most defensible excipient patent opportunity around Pliaglis?

A patent covering a measurable combination of film formation, drying time, drug release, flexibility, and removal performance is likely more defensible than a claim directed only to replacing one conventional excipient with another.

References

1. U.S. Food and Drug Administration. (n.d.). Pliaglis (lidocaine and tetracaine) cream, 7%/7% prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Product-specific guidance for lidocaine and tetracaine topical cream.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
6. Taro Pharmaceutical Industries Ltd. (2024). Annual report and company filings.